Parabilis Medicines, Inc.
No SEC Form 4 filings for $PBLS in the last 30 days.
See all $PBLS insider activity →Parabilis Medicines (PBLS) gained 13% after announcing an upcoming trial readout for its lead drug, zolucatetide, in desmoid tumors. The company is backed by Regeneron (REGN).
Parabilis Medicines (PBLS) began a dose-ranging study of zolucatetide in FAP patients, showing early reductions in polyp burden. The Phase 1/2 trial is ongoing, with more data expected in 2027. Zolucatetide is also being evaluated for other tumors. FAP has no approved systemic therapies.
MediciNova (MNOV) +36%, AbCellera (ABCL) +9%, Parabilis (PBLS) +10%, Haemonetics (HAE), and NeoGenomics (NEO) reached 52-week highs on Sept 17, 2026. MNOV's MN-166 is in Phase 3 trials. ABCL's ABCL635 met primary endpoint in Phase 2. PBLS raised $770.5M in IPO. HAE reported 5.6% revenue growth. NEO's RaDaR ST test got Medicare/Medicaid coverage, revenues up 11%.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning PBLS (Parabilis Medicines, Inc.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent PBLS coverage spans market movers, corporate actions and technology.
The upcoming trial readout is a catalyst that drove a sharp intraday rally, suggesting continued buying pressure ahead of the data release.
Positive early‑stage data may lift investor sentiment toward the biotech.
Post‑IPO momentum and recent FDA designations lifted the stock.
Speculative move.
The CMO exit may cause short-term uncertainty but limited long-term impact.
AlphAI scores every news story that mentions PBLS with an AI model for sentiment and relevance, and aggregates insider trades from Parabilis Medicines, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Parabilis Medicines (PBLS) gained 13% after announcing an upcoming trial readout for its lead drug, zolucatetide, in desmoid tumors. The company is backed by Regeneron (REGN).
1 min readParabilis Medicines (PBLS) began a dose-ranging study of zolucatetide in FAP patients, showing early reductions in polyp burden. The Phase 1/2 trial is ongoing, with more data expected in 2027. Zolucatetide is also being evaluated for other tumors. FAP has no approved systemic therapies.
2 min readMediciNova (MNOV) +36%, AbCellera (ABCL) +9%, Parabilis (PBLS) +10%, Haemonetics (HAE), and NeoGenomics (NEO) reached 52-week highs on Sept 17, 2026. MNOV's MN-166 is in Phase 3 trials. ABCL's ABCL635 met primary endpoint in Phase 2. PBLS raised $770.5M in IPO. HAE reported 5.6% revenue growth. NEO's RaDaR ST test got Medicare/Medicaid coverage, revenues up 11%.
3 min readVicor Corp (VICR) shares rose 13.5% to $208.73 after granting a license for its patents. Other stocks gaining include Securitize (SECZ) +21%, Generac (GNRC) +19.6%, and Arm (ARM) +6.7%. Generac's rise follows a supply deal with Amazon and a price target increase. Micron (MU) gained 5.6% amid a memory stock rally.
2 min readParabilis Medicines, Inc. (PBLS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 28, 2026, Parabilis Medicines, Inc. (the “Company”) and Fawzi Benzaghou, M.D., the Company’s Chief Medical Office
1 min readParabilis Medicines, Inc. (PBLS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors CAMBRIDGE, Mass., August 25, 2026 – Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for pat
1 min readBiotech shares hit 52-week highs on Aug. 17, 2026. OmniAb (OABI) rose to $4.29 after raising 2026 cash flow guidance; Q2 revenue was $13.4M. Iovance (IOVA) reached $7.25 on Q2 revenue growth to $66M and Amtagvi sales. Revolution (RVMD) hit $215.97 on Phase 3 RASolute data for Daraxonrasib. BioLife (BLFS) hit $35.46 after Repligen (RGEN) agreed to buy it for about $1.5B.
5 min readParabilis Medicines, Inc. (PBLS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates Advanced zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors Announced strategic research colla
5 min readBiotech stocks hit 52-week highs Aug 4, 2026 after Q2 results or regulatory updates. UFP Technologies (UFPT) rose over 25% to $338.70, reporting Q2 net income $20.9M and sales $174M. InfuSystem (INFU) gained 33% to $12.49 on $36.9M Q2 revenue and 2026 guidance. Replimune (REPL) jumped to $13.86 after a favorable BLA opinion. SOPHiA (SOPH) rose to $6.98 with $23.3M Q2 revenue and 2026 outlook. Parabilis (PBLS) reached $36.69.
6 min readRA CAPITAL MANAGEMENT, L.P. purchased 244,593 indirectly-held shares of Parabilis Medicines, Inc. (PBLS) at an average of $28.29 ($27.13–$30.00, $6.92M total) across 6 trades over 2026-07-20 to 2026-07-22.
2 min read